江苏拓弘康恒医药

T-Hone Biotech is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the development of next-generation cell therapies for oncology. The company leverages its proprietary dual-target CAR-T and universal CAR-T platforms to address the limitations of current immunotherapies, such as antigen escape and high manufacturing costs. Its lead candidate, TH-007, is a dual-targeting CD19/CD22 CAR-T therapy currently in Phase 2 clinical trials for B-cell malignancies. T-Hone Biotech maintains a comprehensive infrastructure including R&D laboratories and GMP-compliant manufacturing suites to accelerate the translation of its pipeline. The company aims to provide more effective and affordable cell therapy solutions for patients globally through innovative engineering and optimized production processes.